Jiangsu HengRui Medicine Co., Ltd.: Breast Neoplasms trials

The registry lists 46 Breast Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 17 are open to participants now and 0 have results posted.

Phase 1 25Phase 2 12Phase 3 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerNot yet recruitingNCT07894328Phase 3
• A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080Not yet recruitingNCT07876596Phase 1
• A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerRecruitingNCT07358377Phase 1
• A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.RecruitingNCT07354022Phase 3
• A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingNCT07349069Phase 3
• A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingNCT07024173Phase 3
• A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerRecruitingNCT06974929Phase 1/2
• A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsRecruitingNCT06679036Phase 1/2
• Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsNot yet recruitingNCT06592625Phase 2
• A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT06555068Phase 1/2
• Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerRecruitingNCT06222879Phase 1/2
• Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast CancerRecruitingNCT06167694Phase 1/2
• A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.RecruitingNCT05845138Phase 1/2
• A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2
• A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast CancerRecruitingNCT05628870Phase 1
• A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of AdultsEnrolling by invitationNCT05189717Phase 1
• A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationRecruitingNCT04296370Phase 3
• A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy ParticipantsActive, not recruitingNCT07610148Phase 1
• A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.CompletedNCT07320521Phase 1
• A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy ParticipantsCompletedNCT07229560Phase 1
• A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy SubjectsCompletedNCT06619873Phase 1
• A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerActive, not recruitingNCT06057610Phase 3
• SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical TrialActive, not recruitingNCT05814354Phase 3
• A Phase Ib/II Study of SHR-A1811 Injection in Breast CancerStatus unknownNCT05353361Phase 2
• A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast CancerTerminatedNCT05134194Phase 3
• A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast CancerTerminatedNCT05103826Phase 1
• Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeActive, not recruitingNCT04842617Phase 3
• A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)CompletedNCT04613674Phase 3
• Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast CancerCompletedNCT04367090Phase 1
• A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.TerminatedNCT04335006Phase 3
• A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerActive, not recruitingNCT03980054Phase 3
• A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03966898Phase 3
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
• A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03927456Phase 3
• A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerStatus unknownNCT03863223Phase 3
• SHR9549 in ER Positive HER2 Negative Advanced Breast CancerTerminatedNCT03596658Phase 1
• A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerCompletedNCT03481998Phase 1/2
• Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownNCT03080805Phase 3
• A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
• A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerStatus unknownNCT02973737Phase 3
• A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabStatus unknownNCT02422199Phase 1/2
• Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast CancerCompletedNCT02361112Phase 1
• A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving ChemotherapyCompletedNCT02119715Phase 2
• Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast CancerCompletedNCT01937689Phase 1
• A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving ChemotherapyCompletedNCT01611051Phase 3
• Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast CancerTerminatedNCT01301911Phase 1